Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
Rhea-AI Summary
Veru (NASDAQ: VERU) reported fiscal 2025 results and clinical progress for enobosarm in obesity on Dec 17, 2025. Key clinical highlights include FDA regulatory clarity that a ≥5% placebo‑corrected incremental weight loss at 52 weeks or smaller weight difference with clinically meaningful physical function benefit may support approval. Phase 2b PLATEAU (enobosarm 3 mg + GLP‑1 RA) is planned to start Q1 2026 with interim analysis expected Q1 2027. Fiscal 2025 results: cash $15.8M (9/30/25), R&D $15.6M, operating loss $24.8M; company completed a post‑period public offering for ~$23.4M net proceeds.
Positive
- FDA provided regulatory clarity supporting enobosarm development
- Phase 2b PLATEAU planned to start in Q1 2026
- Post‑period public offering net proceeds of approximately $23.4M
- Phase 2b QUALITY: enobosarm 3 mg preserved 100% total lean mass at 16 weeks
- Phase 2b QUALITY: enobosarm 3 mg showed 12% greater fat loss at 16 weeks
Negative
- Cash, cash equivalents and restricted cash were $15.8M as of 9/30/25
- Net loss from continuing operations remained $15.7M in FY2025
- Research and development expense increased to $15.6M in FY2025
- Primary efficacy requirement: 52‑week endpoint required for approval pathway
Market Reaction 15 min delay 2 Alerts
Following this news, VERU has gained 5.74%, reflecting a notable positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $2.58. This price movement has added approximately $2M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
VERU gained 2.09% while close biotech peers were mixed: names like PYPD and ATNM declined, BTAI was flat, and RLMD and VTVT rose. This pattern suggests a company-specific reaction to VERU’s earnings and clinical update rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Earnings date notice | Neutral | -2.3% | Announcement of date and access details for fiscal 2025 results call. |
| Dec 04 | Conference presentations | Positive | +0.8% | Multiple scientific and regulatory presentations on muscle wasting and obesity. |
| Oct 31 | Conference abstracts | Positive | -2.0% | ObesityWeek 2025 abstracts highlighting enobosarm weight and lean-mass effects. |
| Oct 30 | Offering priced | Negative | -14.0% | Dilutive $25M underwritten offering with pre-funded and series warrants. |
| Oct 29 | Offering announced | Negative | -4.1% | Launch of proposed underwritten equity and warrant financing under Form S-3. |
Recent news shows largely aligned moves on financing and event headlines, but past earnings/clinical updates have often seen negative price reactions despite positive data.
Over the last few months, Veru has focused investor attention on enobosarm’s role in obesity treatment and its financing strategy. In late October, a proposed and then priced public offering funded development of the Phase 2b PLATEAU study, and those financing headlines drew clearly negative price reactions. Earlier, conference and abstract presentations around enobosarm’s body-composition benefits produced modest, mixed moves. Today’s full-year results and expanded QUALITY/PLATEAU detail build directly on this sequence, formalizing the financial picture while advancing the obesity program narrative that has underpinned recent capital raises.
Market Pulse Summary
The stock is up +5.7% following this news. A strong positive reaction aligns with the combination of improving loss metrics and advancing clinical clarity. Fiscal 2025 showed reduced operating and net losses while the QUALITY study detailed robust lean-mass preservation and fat loss, and FDA feedback defined approvable obesity endpoints. However, the stock’s longer-term downtrend and history of negative moves after positive data suggest that financing overhangs and execution risk could still limit the durability of gains.
Key Terms
semaglutide medical
placebo-controlled medical
bmi medical
double-blind medical
randomized medical
AI-generated analysis. Not financial advice.
-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA --
-- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements --
-- Company plans to initiate Phase 2 PLATEAU clinical study in calendar Q1 2026 --
-- Post fiscal year end, company completed public offering for net proceeds of approximately
-- Company to host conference call and webcast today at 8:00 a.m. ET --
MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal year 2025 ended September 30, 2025 and provided an update on the clinical progress of its obesity program.
“The current FDA regulatory guidance for muscle preservation drugs in combination with GLP-1 RA drugs in the treatment of obesity seems particularly well aligned for enobosarm,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. “The FDA defines obesity as a disease of excess body fat, and as such, the medical objective to treat obesity should be to reduce excess body fat, NOT to reduce lean mass. Although GLP-1 RAs have demonstrated profound weight loss results, the strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 RAs for patients to ONLY lose fat, while preserving lean mass and physical function for a quality weight reduction. The completed positive Phase 2b QUALITY clinical trial provided the proof of concept that enobosarm could be that next generation drug in combination with a GLP-1 receptor agonist to make the weight loss journey more selective for only fat while preserving lean mass and physical function in older patients who have obesity lessening the potential risk of loss of balance, and fractures.”
Dr. Steiner added: “An emerging, common, and serious clinical and therapeutic challenge with GLP-1 RA monotherapy is that
Enobosarm for chronic weight reduction program
Phase 2b QUALITY study: Enobosarm is a next generation drug that makes GLP-1 RA weight loss more selective for fat loss while preserving lean mass and physical function
In January 2025, the Company announced positive topline efficacy results from the Phase 2b QUALITY clinical study, which was a multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial designed to evaluate the safety and efficacy of enobosarm 3 mg, enobosarm 6 mg, or placebo as a treatment to increase fat loss and to prevent the loss of muscle in 168 older patients (≥60 years of age) receiving a GLP-1 RA (semaglutide) for chronic weight loss.
Highlights from the Phase 2b QUALITY clinical trial focusing on 3 mg enobosarm dose that has been selected by the Company and agreed upon by FDA for the PLATEAU clinical trial
Efficacy
The results for the 16 week active weight loss period of treatment with enobosarm 3 mg or placebo in combination with semaglutide:
- The enobosarm 3 mg + semaglutide group met the primary endpoint of study, preservation of total lean mass, with a statistically significant
100% average preservation of total lean mass compared to placebo + semaglutide at 16 weeks. - Enobosarm + semaglutide treatment resulted in dose dependent greater loss of fat mass compared to placebo + semaglutide with the enobosarm 3 mg group having a
12% greater fat loss at 16 weeks. - Even with having preserved lean mass, enobosarm 3 mg + semaglutide treatment resulted in a similar mean body weight loss as semaglutide alone at 16 weeks. However, it should be noted, in a subset analysis of the subjects receiving enobosarm 3 mg and had a baseline BMI ≥ 35, incremental weight loss was observed at 16 weeks:
- There was weight loss of -
4.7% for semaglutide versus -5.58% for enobosarm 3 mg + semaglutide treatment group. - Proportion of patients that lost at least
5% of body weight at 16 weeks was47.4% for semaglutide vs65.4% for enobosarm 3 mg + semaglutide treatment group. - This weight loss occurred even with
84% preservation of lean mass in this subset of patients receiving semaglutide on enobosarm 3 mg.
- There was weight loss of -
- The tissue composition of the total body weight lost on average was
34% lean mass and66% fat mass in the placebo and semaglutide group, whereas for the enobosarm 3 mg + semaglutide group, the weight loss was0% lean mass and100% fat mass.
- Physical function was measured by the Stair Climb Test. A prespecified responder analysis was conducted using a greater than
10% decline in stair climb power as the cut off at 16 weeks which is a decline that represents an approximate 7 to 8 years of loss of stair climb power function that naturally occurs with aging, but it occurred in 16 weeks.
- Semaglutide alone resulted in a loss of physical function as
44.8% of the placebo + semaglutide group had at least a10% decline in stair climb power physical function at 16 weeks. The Phase 2b QUALITY study is the first to confirm that older patients with obesity receiving a GLP-1 RA had a significant and relevant physical function decline as early as 16 weeks on treatment. - In contrast, enobosarm 3 mg treatment reduced the proportion of patients receiving semaglutide to
17.6% who experienced ≥10% decline in stair climb power. This represents a59.8% relative reduction in proportion of patients receiving enobosarm who experienced ≥10% decline in stair climb power.
- Semaglutide alone resulted in a loss of physical function as
Results for the Maintenance Extension portion of the study, where all patients discontinued semaglutide treatment, but continued receiving placebo, enobosarm 3 mg as monotherapy for 12 weeks:
- The placebo monotherapy group regained
43% of body weight that was previously lost during the Phase 2b QUALITY study for a mean percent change of2.57% (5.06 lbs) in body weight, compared to1.41% (2.73 lbs) for the 3 mg enobosarm group. This means that the 3 mg enobosarm monotherapy significantly reduced the body weight regained by46% after discontinuation of semaglutide. - By the way, the mean tissue composition of body weight regained was
100% lean mass, not fat for the enobosarm 3 mg compared to28% fat and72% lean mass in the placebo group.
- In fact, by end of the 28 week study, enobosarm 3 mg plus semaglutide followed by enobosarm 3 mg monotherapy regimen was more effective in preserving
100% lean mass and in losing58% more fat compared to placebo plus semaglutide followed by placebo monotherapy.
Safety
At the end of the 16 week active weight loss period, enobosarm and semaglutide combination had a positive safety profile and enobosarm did not have any added gastrointestinal (GI) adverse events compared to semaglutide alone. For the Maintenance Extension clinical trial, where semaglutide was stopped for 12 weeks, enobosarm monotherapy also had a positive safety profile. After discontinuation of semaglutide, there were essentially no GI side effects, no evidence of drug induced liver injury, and no increases in obstructive sleep apnea observed at any dose of enobosarm compared to placebo monotherapy. There were no AEs related to masculinization in women. There were no AEs of increases in prostate specific antigen in men.
Summary
The Phase 2b QUALITY clinical trial confirms that preserving lean mass with enobosarm plus semaglutide led to greater fat loss during the active weight loss period, and after semaglutide was discontinued, enobosarm monotherapy significantly prevented the regain of both weight and fat mass such that by the end of the 28 week study there was greater loss of fat mass while preserving lean mass for a higher quality weight reduction compared to the placebo group.
FDA Regulatory Feedback
In September 2025, the Company announced a successful FDA meeting providing regulatory clarity for enobosarm in combination with GLP-1 RA for greater weight loss in the treatment of obesity
Highlights from September 2025 FDA meeting
Incremental weight loss: According to FDA feedback on Veru’s clinical development program for enobosarm, FDA has guided us that there are at least 2 possible regulatory pathways forward for the development of enobosarm in combination with a GLP-1 RA and are based on incremental weight loss. First, incremental weight loss with at least a
Enobosarm dose - FDA confirmed that enobosarm 3 mg is an acceptable dosage for future Veru clinical development.
Planned Phase 2b PLATEAU clinical study
The planned Phase 2b PLATEAU clinical trial will measure incremental weight loss in this enriched patient population that has more weight to lose (BMI ≥ 35) and more at risk for physical decline and functional limitations (age ≥ 65) to better inform the design of the Phase 3 development program. For the planned Phase 2b PLATEAU clinical trial, we will evaluate the effect of enobosarm 3 mg on total body weight, physical function, and safety in approximately 200 patients who have obesity (BMI ≥ 35) and are older (age ≥ 65) and are initiating GLP-1 RA treatment for weight reduction. The primary efficacy endpoint of the study will be the percent change from baseline in total body weight at 72 weeks. An interim analysis will be conducted at 36 weeks to assess the percent change from baseline in lean body mass and fat mass, as measured by DEXA scan. Since we want to continue to evaluate enobosarm as a muscle preserving and body composition drug, the key secondary endpoints will be function endpoints, physical function (stair climb test), mobility disability status (functional limitations), and patient reported outcome questionnaires for physical function (SF-36 PF-10, and IWQOL-lite CT physical function) as well as body composition endpoints, total fat mass, total lean mass, and bone mineral density.
Building on the Phase 2 QUALITY study and with greater FDA regulatory clarity, we have designed the Phase 2b PLATEAU clinical study to assess the ability of enobosarm treatment to break through the weight loss plateau in older patients (age ≥ 65) with obesity (BMI ≥ 35) receiving GLP-1 RA treatment with the expectation that patients will achieve clinically meaningful incremental weight reduction and preserve muscle mass and physical function at 52 weeks of GLP-1 weight reduction maintenance dose.
Full Year Financial Summary: Fiscal 2025 vs Fiscal 2024
- Research and development expenses increased to
$15.6 million from$12.8 million - General and administrative expenses decreased to
$19.9 million from$24.6 million - Operating loss from continuing operations decreased to
$24.8 million from$36.2 million - Net loss from continuing operations decreased to
$15.7 million , or$1.07 per share, compared to$35.3 million , or$2.61 per share - Net loss decreased to
$22.7 million , or$1.55 per share, compared to$37.8 million , or$2.80 per share
Balance Sheet Information
- Cash, cash equivalents and restricted cash were
$15.8 million as of September 30, 2025 versus$24.9 million as of September 30, 2024 - Post fiscal 2025 year end, company completed public offering for additional net cash proceeds of approximately
$23.4 million
Event Details
The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available at approximately 12:00 p.m. ET by dialing 1-855-669-9658 (domestic) or 1-412-317-0088 (international), passcode 2225332, for one week.
About Veru Inc.
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass leading to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.
Enobosarm Obesity Program - Enobosarm is a next generation drug that in combination with GLP-1 RA results in higher quality weight reduction
The Phase 2b QUALITY clinical study was a positive multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial designed to evaluate the safety and efficacy of enobosarm 3 mg, enobosarm 6 mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in 168 older patients (≥60 years of age) receiving semaglutide (Wegovy®) for weight reduction. After completing the efficacy dose-finding portion of the Phase 2b QUALITY clinical trial ended at 16 weeks, participants continued into a Phase 2b maintenance extension study where all patients discontinued semaglutide treatment, but continued receiving placebo, enobosarm 3 mg, or enobosarm 6 mg as monotherapy in a double-blind fashion for 12 weeks. The Phase 2b QUALITY and Maintenance Extension clinical trial was a positive study that demonstrated that preserving lean mass and physical function with enobosarm plus semaglutide led to greater fat loss during the 16 week active weight loss period. While weight loss was similar across treatment groups in this short 16 week study, we anticipate that preservation of lean mass and function will lead to increased energy expenditure, and this effect coupled with the direct effects of enobosarm on the additional selective reduction in fat mass will result in incremental weight reduction in a longer clinical study in patients who have obesity.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to the planned design, enrollment, timing, commencement, interim and full data readout timing, scope and regulatory pathways for the continued development of enobosarm in patients with obesity, including the planned PLATEAU Phase 2b study; whether clinically meaningful incremental weight loss in the PLATEAU Phase 2b study will continue to be seen as an acceptable primary endpoint by the FDA to support potential approval; whether the FDA will continue to accept 3 mg as an acceptable dosage for enobosarm in the planned PLATEAU Phase 2b study or in any other studies; whether the FDA will further evolve its position on the acceptable patient population for the PLATEAU Phase 2b study or any other future studies; whether the Company will be able to partner with any other company in the development of enobosarm; whether the results of the Phase 2b QUALITY study and the extension maintenance study of enobosarm, including weight loss, preservation of lean mass and physical function and loss of fat mass, will be replicated to the same or any degree in the planned PLATEAU Phase 2b study or in any future Phase 3 studies; whether patients treated with enobosarm in the planned PLATEAU Phase 2B study will exhibit increased energy and whether such effects will result in incremental weight reduction; whether enobosarm will reduce body weight regain for patients discontinuing GLP-1 RA or reaching weight loss plateau; whether outcome questionnaires for evaluating physical function can be developed that will be accepted by the FDA or support drug approval; whether the Company will be able to raise sufficient capital, dilutive or otherwise, to fund the PLATEAU Phase 2b study of enobosarm in patients with obesity or any other studies; whether the Company will be able to recruit a sufficient number of patients in a timely manner for the PLATEAU Phase 2b study; whether the Company will be able to obtain sufficient GLP-1 RA drugs in a timely or cost-effective manner in the planned PLATEAU Phase 2b study; whether the Company will be able to engage clinical research organizations and recruit patients for the PLATEAU Phase 2b program and in a timely or cost-effective manner; whether enobosarm will cause weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will cause weight loss in the planned PLATEAU Phase 2b study or any future Phase 3 studies or, if approved and commercialized, in clinical practice; whether patients treated with enobosarm for a longer period of time than in the Phase 2b QUALITY study will experience weight loss or have a greater loss of body fat or greater weight loss than with GLP-1 RA drug alone; whether and when enobosarm will be approved by the FDA as a weight loss drug or a body composition drug or any other type of drug; and whether and when the Company will be able to further advance the development of sabizabulin in atherosclerotic disease. The words "anticipate," "believe," "could," "expect," "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statements contained in this press release because of new information or future events, developments, or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to: the development of the Company’s product portfolio and the results of clinical studies, including any interim analysis, possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; although the Company has sought and received feedback from FDA on the designs of its clinical trials and intends to continue to do so, FDA may ultimately disagree that the Company’s clinical trials support approval; the Company’s ability to reach agreement with FDA on study design requirements for the Company’s planned clinical studies, including for the Phase 2b program for enobosarm as a weight loss or body composition drug and the number of future Phase 3 studies to be required and the cost thereof; potential delays in the timing of and results from clinical trials and studies, including as a result of an inability to enroll sufficient numbers of subjects in clinical studies or an inability to enroll subjects in accordance with planned schedules; the ability to fund planned clinical development as well as other operations of the Company; the timing of any submission to the FDA or any other regulatory authority and any determinations made by the FDA or any other regulatory authority; the potential for disruptions at the FDA or other government agencies to negatively affect our business, including as a result of a future shutdown of the U.S. government; any products of the Company, if approved, possibly not being commercially successful; the ability of the Company to obtain sufficient financing, including any partnership or collaboration agreements, on acceptable terms when needed to fund development and operations and to enable us to continue as a going concern; demand for, market acceptance of, and competition against any of the Company’s products or product candidates; new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes; the Company’s ability to protect and enforce its intellectual property; costs and other effects of litigation, including regulatory challenges, product liability claims, intellectual property, securities litigation and litigation with the purchaser of the Company’s FC2 business; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2024, and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors.
Wegovy® is a registered trademark of Novo Nordisk A/S.
FINANCIAL SCHEDULES FOLLOW
| Veru Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (unaudited) | |||||||
| September 30, | September 30, | ||||||
| 2025 | 2024 | ||||||
| Cash, cash equivalents and restricted cash | $ | 15,794,562 | $ | 24,916,285 | |||
| Investment in equity securities | 2,525,305 | 742,295 | |||||
| Prepaid expenses and other current assets | 595,251 | 805,633 | |||||
| Current assets of discontinued operations | — | 8,759,011 | |||||
| Total current assets | 18,915,118 | 35,223,224 | |||||
| Property and equipment, net | 364,808 | 481,372 | |||||
| Operating lease right-of-use asset | 2,746,014 | 3,250,623 | |||||
| Goodwill | 6,878,932 | 6,878,932 | |||||
| Other assets | 930,847 | 989,596 | |||||
| Long-term assets of discontinued operations | — | 13,595,025 | |||||
| Total assets | $ | 29,835,719 | $ | 60,418,772 | |||
| Accounts payable | $ | 3,121,448 | $ | 2,259,668 | |||
| Accrued compensation | 3,510,237 | 4,494,278 | |||||
| Accrued expenses and other current liabilities | 1,153,475 | 1,406,655 | |||||
| Residual royalty agreement, short-term portion | — | 1,025,837 | |||||
| Current liabilities of discontinued operations | — | 2,681,530 | |||||
| Total current liabilities | 7,785,160 | 11,867,968 | |||||
| Residual royalty agreement, long-term portion | — | 8,850,792 | |||||
| Operating lease liability, long-term portion | 2,358,018 | 2,905,309 | |||||
| Other liabilities | 1,359,871 | 4,477,991 | |||||
| Total liabilities | 11,503,049 | 28,102,060 | |||||
| Total stockholders' equity | 18,332,670 | 32,316,712 | |||||
| Total liabilities and stockholders' equity | $ | 29,835,719 | $ | 60,418,772 | |||
| Veru Inc. | |||||||
| Condensed Consolidated Statements of Operations | |||||||
| (unaudited) | |||||||
| Year Ended | |||||||
| 2025 | 2024 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 15,588,185 | $ | 12,782,167 | |||
| General and administrative | 19,942,747 | 24,609,801 | |||||
| Total operating expenses | 35,530,932 | 37,391,968 | |||||
| Gain on sale of ENTADFI® assets | 10,780,290 | 1,222,908 | |||||
| Operating loss | (24,750,642 | ) | (36,169,060 | ) | |||
| Total non-operating income | 9,069,385 | 909,122 | |||||
| Net loss from continuing operations | (15,681,257 | ) | (35,259,938 | ) | |||
| Net loss from discontinued operations, net of taxes | (7,045,022 | ) | (2,541,488 | ) | |||
| Net loss | $ | (22,726,279 | ) | $ | (37,801,426 | ) | |
| Net loss from continuing operations per basic and diluted common shares outstanding | $ | (1.07 | ) | $ | (2.61 | ) | |
| Net loss from discontinued operations per basic and diluted common shares outstanding | $ | (0.48 | ) | $ | (0.19 | ) | |
| Net loss per basic and diluted common shares outstanding | $ | (1.55 | ) | $ | (2.80 | ) | |
| Basic and diluted weighted average common shares outstanding | 14,646,294 | 13,487,502 | |||||
| Veru Inc. | |||||||
| Condensed Consolidated Statements of Cash Flows | |||||||
| (unaudited) | |||||||
| Year Ended | |||||||
| 2025 | 2024 | ||||||
| Net loss | $ | (22,726,279 | ) | $ | (37,801,426 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities | (3,187,918 | ) | 15,896,600 | ||||
| Changes in operating assets and liabilities | (4,128,891 | ) | 222,493 | ||||
| Net cash used in operating activities | (30,043,088 | ) | (21,682,333 | ) | |||
| Net cash provided by investing activities | 25,142,976 | 146,214 | |||||
| Net cash (used in) provided by financing activities | (4,221,611 | ) | 36,826,910 | ||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (9,121,723 | ) | 15,290,791 | ||||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF YEAR | 24,916,285 | 9,625,494 | |||||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR | $ | 15,794,562 | $ | 24,916,285 | |||
Investor and Media Contact:
Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: veruinvestor@verupharma.com
FAQ
What did Veru announce about FDA guidance for enobosarm (VERU) on Dec 17, 2025?
When will Veru start the Phase 2b PLATEAU study for enobosarm (VERU)?
What were the key Phase 2b QUALITY results for enobosarm (VERU) relevant to investors?
How much cash did Veru report and did it raise additional funds after fiscal year end?
What are the primary and key secondary endpoints in the PLATEAU trial for VERU?
Does Veru expect enobosarm to address the GLP‑1 weight loss plateau (VERU)?
